{"created":"2023-07-27T06:53:03.380681+00:00","id":47336,"links":{},"metadata":{"_buckets":{"deposit":"1558bf05-4cfb-41d0-84b1-5530ad708d3d"},"_deposit":{"created_by":18,"id":"47336","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"47336"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00047336","sets":["1132:1133:1134"]},"author_link":["83290","68019","20454","83264","83576","83573","45392","21459","83571","83572","45215","83498","329","83569","83570","3019"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"328","bibliographicPageStart":"323","bibliographicVolumeNumber":"33","bibliographic_titles":[{"bibliographic_title":"Biomedical Research (Japan)"}]}]},"item_4_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"角野, 佳史"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"三輪, 聰太郎"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"小中, 弘之"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"溝上, 敦 "}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"並木, 幹夫"}],"nameIdentifiers":[{},{}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Interferon-alpha (IFN-α) has been used in systemic treatment for metastatic renal cell carcinoma (mRCC). IFN-α has at least 14 subtypes, each of which has different biological activity. There have been reports that mRCC resistant to an IFN-α treatment responded to another IFN-α subtype. This study was performed to evaluate the effectiveness of alternation of different IFN-α subtypes for mRCC that did not respond to initial IFN-α treatment. In our department and associated institutions, alternating therapy of IFN-α was provided for 15 initial IFN-α refractory mRCC cases from June 2005 to September 2008. Among the 15 patients, the effects of alternating IFN-α therapy were as follows: complete response (CR), 0 cases; partial response (PR), 1 case; stable disease (SD), 3 cases; progressive disease (PD), 11 cases. The response rate (CR+PR) was 7% and disease control rate (CR+PR+SD) was 27%. No severe side effects were observed in any of these cases. The PR case is still in PR 21 months after alternating IFN-α therapy. Among the three SD cases, one has continued SD for 14 months and the other for 12 months. Alternating IFN-α therapy for mRCC can be attempted even if other cytokines are not effective. © 2012 Biomedical Research Press.","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_4_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00053663","subitem_identifier_reg_type":"JaLC"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Biomedical Research Foundation"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2220/biomedres.33.323","subitem_relation_type_select":"DOI"}}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://www.jstage.jst.go.jp/browse/biomedres/-char/ja/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jstage.jst.go.jp/browse/biomedres/-char/ja/","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 2012 Biomedical Research Press."}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA00110128","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0388-6107","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kadono, Yoshifumi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Miwa, Sotaro"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Shima, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Konaka, Hiroyuki"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Mizokami, Atsushi"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Yotsuyanagi, Satoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hirata, Akio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takase, Yasukazu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sugata, Toshiaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shimamura, Masayoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Namiki, Mikio"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-03-08"}],"displaytype":"detail","filename":"ME-PR-NAMIKI-M-323.pdf","filesize":[{"value":"307.0 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-NAMIKI-M-323.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/47336/files/ME-PR-NAMIKI-M-323.pdf"},"version_id":"2faf717f-92a4-466b-8378-ceadd869bd2b"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma"}]},"item_type_id":"4","owner":"18","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-03-08"},"publish_date":"2019-03-08","publish_status":"0","recid":"47336","relation_version_is_last":true,"title":["The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T16:34:47.118970+00:00"}